Kingway financial news | Nomura released a research report, according to reports on October 3rd, Wuxi Apptec (02359) and wuxi bio (02269) are considering selling parts of their business units due to uncertainties related to the Biosecurity Law. The report indicates that wuxi apptec has put up for sale one of its business units (BU) the gene therapy CTDMO business, and is currently testing the market's interest in acquiring a production facility in Germany, which was acquired from Bayer in 2021.
The bank estimates that wuxi bio's production facility in Germany accounts for 6% of the company's total capacity. The bank believes that if the above-mentioned business sales are completed, investors are expected to react more positively to wuxi apptec relative to wuxi bio.
